Holen Sie sich die Stockscreener-App
0.9702
8.89%
0.0792
Handel nachbörslich:
1.00
0.0298
+3.07%
Schlusskurs vom Vortag:
$0.891
Offen:
$0.95
24-Stunden-Volumen:
652.02K
Relative Volume:
0.95
Marktkapitalisierung:
$45.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.65M
KGV:
-0.581
EPS:
-1.67
Netto-Cashflow:
$-24.14M
1W Leistung:
-5.81%
1M Leistung:
+10.63%
6M Leistung:
-21.76%
1J Leistung:
-29.18%
1-Tages-Spanne:
$0.90
$1.01
1-Wochen-Bereich:
$0.8515
$1.16
52-Wochen-Spanne:
$0.485
$4.28
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
Firmenname
Reviva Pharmaceuticals Holdings Inc
Sektor
Branche
Telefon
(408) 501-8881
Adresse
10080 N WOLFE ROAD, CUPERTINO
Vergleichen Sie RVPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVPH
Reviva Pharmaceuticals Holdings Inc
|
0.9702 | 48.14M | 0 | -37.65M | -24.14M | -1.67 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-20 | Eingeleitet | ROTH MKM | Buy |
| 2023-06-08 | Eingeleitet | The Benchmark Company | Speculative Buy |
| 2022-01-24 | Eingeleitet | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc Aktie (RVPH) Neueste Nachrichten
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Shares Sold by Millennium Management LLC - Defense World
Reviva Pharmaceuticals Launches $50M At-Market Offering - TipRanks
Reviva Pharmaceuticals Holdings IncEnters Into At Market Issuance Sales AgreementSEC Filing - marketscreener.com
What is Zacks Small Cap’s Estimate for RVPH Q2 Earnings? - Defense World
Roth Capital Issues Positive Forecast for RVPH Earnings - Defense World
D. Boral Capital Lowers Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target to $3.00 - Defense World
Reviva Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Reviva stock target cut to $3 on cash concerns, retains Buy rating - Investing.com Australia
Spotify To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday - NewsBreak: Local News & Alerts
Reviva to Participate in Upcoming Investor Conferences in May 2025 - GlobeNewswire
Late-Stage CNS Drug Developer Reviva Opens Access to Management at Benchmark and Lytham Conferences - Stock Titan
Reviva Pharmaceuticals (RVPH): Analyst Maintains Buy Rating, Low - GuruFocus
Reviva Pharmaceuticals (RVPH) Sees Price Target Reduction Amid Funding Concerns | RVPH Stock News - GuruFocus
Reviva Pharmaceuticals (RVPH): Analyst Maintains Buy Rating, Lowers Price Target | RVPH Stock News - GuruFocus
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Reviva Pharmaceuticals (RVPH) Advances Brilaroxazine Program Tow - GuruFocus
Reviva Pharmaceuticals (RVPH) Advances Brilaroxazine Program Towards Approval | RVPH Stock News - GuruFocus
Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Major Milestone: 446 Patients Complete Reviva's Schizophrenia Drug Trial, Full Results Expected Q2 2025 - Stock Titan
Reviva to Participate in the A.G.P. Healthcare Company Showcase - GlobeNewswire
Tower Research Capital LLC TRC Has $48,000 Stock Holdings in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals (RVPH) Expected to Announce Earnings on Tuesday - Defense World
Short Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Grows By 30.5% - Defense World
Geode Capital Management LLC Grows Position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight - GlobeNewswire Inc.
Reviva to Participate in the Citizens Life Sciences Conference - GlobeNewswire
Reviva Pharma CEO Takes Center Stage: Key Updates Coming at Major Life Sciences Conference - Stock Titan
Gaining Ground: Reviva Pharmaceuticals Holdings Inc (RVPH) Closes Lower at 0.86, Down -4.98 - DWinneX
Market Update: American Rebel Holdings Inc (AREB) Sees Negative Movement, Closing at 3.85 - DWinneX
Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire
D. Boral Capital Reiterates “Buy” Rating for Reviva Pharmaceuticals (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals Holdings Inc Inc. (RVPH) Price Performance: The Role of Supply and Demand - investchronicle.com
Reviva to Present Late-Breaking Poster on the RECOVER - GlobeNewswire
Major Phase 3 Breakthrough: Reviva Unveils 12-Month Schizophrenia Treatment Data at ASCP 2025 - Stock Titan
Investing in Reviva Pharmaceuticals Holdings Inc (RVPH) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - uspostnews.com
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Reviva Pharmaceuticals (RVPH) to Release Earnings on Monday - Defense World
RVPH: M&A Deals Highlight Brilaroxazine Value - MSN
What is Roth Capital’s Forecast for RVPH Q1 Earnings? - Defense World
Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results - streetwisereports.com
Reviva Pharmaceuticals Holdings Inc. (RVPH) reports earnings - qz.com
Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target Lowered to $8.00 at D. Boral Capital - Defense World
Reviva Pharmaceuticals Reports 2024 Financial Results - TipRanks
RVPH stock touches 52-week low at $0.6 amid market challenges - Investing.com Australia
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Reviva Pharmaceuticals Delays Annual Report Filing - TipRanks
Reviva Pharmaceuticals Holdings Files For Non-Timely 10-KSEC Filing - MarketScreener
Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Breakthrough: Reviva's Schizophrenia Treatment Delivers Powerful 1-Year Results, Losses Narrow - Stock Titan
Reviva to Present Brilaroxazine Topline Data for Long-Term - GlobeNewswire
Finanzdaten der Reviva Pharmaceuticals Holdings Inc-Aktie (RVPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):